Clinical Trials Directory

Trials / Conditions / Recurrent Acute Biphenotypic Leukemia

Recurrent Acute Biphenotypic Leukemia

7 registered clinical trials studyying Recurrent Acute Biphenotypic Leukemia — 2 currently recruiting.

StatusTrialSponsorPhase
TerminatedOmacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplast
NCT04874194
M.D. Anderson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingVenetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute M
NCT04975919
M.D. Anderson Cancer CenterPhase 2
TerminatedFludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
NCT04526795
M.D. Anderson Cancer CenterPhase 1
WithdrawnRivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem C
NCT03807063
Fred Hutchinson Cancer CenterPhase 1
RecruitingCladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Re
NCT04047641
M.D. Anderson Cancer CenterPhase 1 / Phase 2
RecruitingHA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After
NCT03326921
Fred Hutchinson Cancer CenterPhase 1
TerminatedVenetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed
NCT03404193
M.D. Anderson Cancer CenterPhase 2